drugset
drugset / Trial / NCT07570069

Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants

NCT07570069 ↗

Phase 1 Active not recruiting 18 enrolled Vertex Pharmaceuticals Incorporated
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the pharmacokinetics (PK) of Suzetrigine (SUZ) and its metabolite in the absence and presence of efavirenz, a moderate CYP3A inducer. In addition, the purpose is to evaluate the safety and tolerability of SUZ when administered in the absence and presence of efavirenz.

Timeline

Start
2026-05-07
Primary completion
2026-07-11
Completion
2026-07-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Efavirenz Other / unclassified — Oral
Subject Suzetrigine Small molecule — Oral

Indications

No indication recorded.